- Home
- EVV vs COGT Comparison
EVV vs COGT Comparison
Compare EVV & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVV
- COGT
- Stock Information
- Founded
- EVV 2003
- COGT 2014
- Country
- EVV United States
- COGT United States
- Employees
- EVV N/A
- COGT N/A
- Industry
- EVV Finance/Investors Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- EVV Finance
- COGT Health Care
- Exchange
- EVV Nasdaq
- COGT Nasdaq
- Market Cap
- EVV 1.2B
- COGT 1.1B
- IPO Year
- EVV N/A
- COGT 2018
- Fundamental
- Price
- EVV $10.17
- COGT $15.52
- Analyst Decision
- EVV
- COGT Strong Buy
- Analyst Count
- EVV 0
- COGT 11
- Target Price
- EVV N/A
- COGT $21.20
- AVG Volume (30 Days)
- EVV 323.7K
- COGT 2.1M
- Earning Date
- EVV 01-01-0001
- COGT 11-11-2025
- Dividend Yield
- EVV 9.66%
- COGT N/A
- EPS Growth
- EVV N/A
- COGT N/A
- EPS
- EVV N/A
- COGT N/A
- Revenue
- EVV N/A
- COGT N/A
- Revenue This Year
- EVV N/A
- COGT N/A
- Revenue Next Year
- EVV N/A
- COGT N/A
- P/E Ratio
- EVV N/A
- COGT N/A
- Revenue Growth
- EVV N/A
- COGT N/A
- 52 Week Low
- EVV $8.52
- COGT $3.72
- 52 Week High
- EVV $10.07
- COGT $16.22
- Technical
- Relative Strength Index (RSI)
- EVV 48.79
- COGT 71.71
- Support Level
- EVV $10.07
- COGT $13.72
- Resistance Level
- EVV $10.23
- COGT $16.22
- Average True Range (ATR)
- EVV 0.08
- COGT 0.69
- MACD
- EVV -0.01
- COGT 0.24
- Stochastic Oscillator
- EVV 52.63
- COGT 85.02
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.